New Federal Data Maps How Adulterants Spread Through the U.S. Fentanyl Supply

On October 8, 2026, the National Institute of Standards and Technology (NIST) released findings that answer a question public health officials have struggled with for years: what, exactly, is mixed into the illegal fentanyl supply — and how does that change from one part of the country to another? The study, published in the journal Drug Testing and Analysis, is one of the first large-scale looks at how fentanyl adulterants move across the United States over time.

For anyone who uses drugs, or loves someone who does, the takeaway is practical rather than academic: the substance in front of you is probably not just fentanyl, and most of the tools used to check it will not tell you what else is in there.

What the researchers found

NIST chemist Edward Sisco and his colleagues analyzed 4,563 samples of drug residue collected nationwide between January 2024 and June 2026. The samples came through NIST's Rapid Drug Analysis and Research program, known as RaDAR, which works with public health agencies, law enforcement, forensic laboratories and medical examiner offices across the country.

Rather than the slow, column-based testing used in most crime labs, RaDAR uses a technique called Direct Analysis in Real Time Mass Spectrometry (DART-MS). It produces a chemical fingerprint of each sample in seconds and can pick up trace amounts of compounds that would otherwise go unnoticed. Results go back to partner agencies within 48 hours.

The team found that adulterants are not spread evenly. They appear in different regions at different times, and they move in recognizable patterns. Xylazine, a veterinary sedative, moved from the Northeast into the Mid-Atlantic and then westward. Sisco said the data lets researchers watch an additive travel "from Philadelphia, down to Delaware and Maryland, and then out west."

The team is now building models to predict that movement. The goal, Sisco said, is that when a new additive appears in one city, health officials elsewhere can be told roughly when to expect it. NIST is planning similar surveys for additives in ketamine and for a newer class of synthetic opioids known as orphines.

The supply is a mixture — and much of it is not an opioid

The compounds NIST and its partners have documented include anesthetics, industrial chemicals and veterinary sedatives — among them xylazine, medetomidine, nitazenes and an industrial chemical called BTMPS.

That changes what an overdose actually is. Xylazine is not an opioid, and it causes wounds so severe that amputation may be necessary if they are left untreated. Medetomidine, a more potent and longer-acting veterinary sedative, prompted a national CDC Health Advisory (HAN-00527) warning of overdose risk and a severe withdrawal syndrome that is difficult to treat. We have covered medetomidine's spread in detail before, and the blog's earlier reporting on xylazine is here.

Because these compounds are not opioids, naloxone — the medicine that reverses opioid overdoses — does not undo them. A person can be revived from the opioid portion of a mixture and still be dangerously sedated, still have an untreated wound, still be at risk. When opioids are combined with sedatives, breathing slows further.

The NIST release put the stakes plainly: telling first responders which adulterants are in the local supply, it said, "may make the difference between life and death."

Why a test strip is not a guarantee

Fentanyl test strips are one of the most useful tools available — cheap, fast, and simple enough to use at home. But they answer a single question: is fentanyl present? They do not reliably detect xylazine, medetomidine, benzodiazepines or newer synthetic opioids, and hospital drug screens often miss the same compounds for the same reason. Most of the harmful substances NIST tracked are not opioids at all, so a screen built to find opioids will not see them.

That is why a negative result is information, not clearance. Someone can test a supply, get a negative result for fentanyl, and still be taking something unknown and more potent than expected. Our guide to fentanyl test strips and drug checking explains how to use the strips correctly and what their results do and do not mean.

The newer opioids compound the problem. Orphines, the class NIST now plans to survey, are synthetic opioids with no approved medical use; some are more potent than morphine but less potent than fentanyl by weight, while others have not been studied well enough in humans to know. They can cause the same sedation, pinpoint pupils and slowed breathing as other opioids, and they are not what standard testing is looking for.

What to do

For people who use drugs, harm-reduction guidance has not changed — but this data is a reminder of why each step matters:

• Do not use alone. Using with someone else, or leaving a door unlocked and checking in with a friend, means someone can call for help.
• Start small. The supply is unevenly mixed, so a small test amount can reveal a dose that is stronger than expected.
• Keep naloxone within reach, and know its limits. Naloxone works for about 30 to 90 minutes, while many opioids stay in the body longer — the overdose can return. It reverses opioids only. Our guide to getting naloxone covers where to find it and how to use it.
• Use fentanyl and xylazine test strips when you can, and treat the result carefully. A negative strip does not mean the supply is clean; it means fentanyl was not detected in that sample.
• Look after the skin. Any wound should be cleaned and checked by a clinician early, not left to heal on its own.
• Do not trust a pill by its appearance. Counterfeit pills are made to look like legitimate medication.
• Call 911 in an overdose, and know that most states have Good Samaritan laws that protect callers from drug charges.

Families can help by keeping naloxone in the home, learning the signs of an overdose, and talking about the supply without turning it into an argument.

Where to get help

• SAMHSA National Helpline: 1-800-662-4357 — free, confidential, 24 hours a day, in English and Spanish.
• FindTreatment.gov — search for treatment near you.
• 988 Suicide and Crisis Lifeline — call or text 988.
• Medications for opioid use disorder — buprenorphine, methadone and naltrexone have the strongest evidence for reducing overdose death. A clinician or local health department can help you start.
• Local harm-reduction programs — many distribute naloxone and test strips at no cost through health departments and community organizations.

The bottom line

The U.S. fentanyl supply is a moving mixture, and the science now tracks it region by region. Until that information reaches every community, the safest position is the one harm-reduction workers have held for years: assume the supply is unpredictable, never use alone, and keep naloxone close.